EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024

Code: GDHCER107-15 | Published: Jan-2016 | Pages: 47 | GlobalData
Price :
$3,995.00
USD

* Required Fields

$3,995.00

Details

EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024

Summary

Small Cell Lung Cancer (SCLC) is a distinct form of lung cancer that typically initially presents in the central airways before spreading to the submucosa, which leads to the narrowing of airways. SCLC is considered to be highly malignant due to its cell composition that causes faster doubling time, earlier development of metastases, and worsened prognosis when compared with other lung cancer types. SCLC is widely considered to account for 15% of all lung cancer cases, with the other lung cancer cases being predominantly caused by non-small cell lung cancer (NSCLC). SCLC is typically presented in two main stages, limited stage (LS-SCLC) and extensive stage (ES-SCLC).

GlobalData epidemiologists forecast that the diagnosed incident cases of SCLC will increase from 79,077 cases in 2014 to 91,640 cases in 2024 across the 7MM with an Annual Growth Rate (AGR) of 1.59%. The US had the highest proportion of SCLC diagnosed incident cases out of the 7MM throughout the forecast period. In 2014, there were 23,361 LS-SCLC diagnosed incident cases and 55,716 ES-SCLC diagnosed incident cases in the 7MM, accounting for 29.54% and 70.46% of the total SCLC diagnosed incident cases, respectively. Further, GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of SCLC will increase from 59,330 cases in 2014 to 71,528 cases in 2024 with an AGR of 2.06%. Out of the 7MM, Japan had the highest proportion of SCLC five-year diagnosed prevalent cases across the forecast period.

GlobalDatas epidemiological forecast for the diagnosed incident and the five-year diagnosed prevalent cases of SCLC in the 7MM is supported by age- and sex-specific incidence data obtained for the individual markets. Further, the analysis was strengthened by the use of a consistent methodology and definition of lung cancer for the diagnosed incident cases in the SCLC forecast, and using linear regression techniques when suitable. In addition, the forecast is based on age-, sex-, and market-specific historical data points obtained from the NCC, CI5plus, ITACAN, SEER, and ZfKD databases. The use of a consistent methodology across the 7MM to forecast the total diagnosed incident cases, and the five-year diagnosed prevalent cases of SCLC, allows for a meaningful comparison of the forecast incident cases and the forecast five-year prevalent cases of SCLC across the 7MM. Further, GlobalData epidemiologists provided the diagnosed incident cases of SCLC in the 7MM segmented into LS-SCLC and ES-SCLC at diagnosis.

Scope

- The Small Cell Lung Cancer (SCLC) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for RSV infection in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of SCLC and the five-year diagnosed prevalent cases of SCLC segmented by sex, age (beginning at 18 years and ending at =85 years), and stage in these markets.
- The SCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

The Small Cell Lung Cancer (SCLC) EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SCLC market.
- Quantify patient populations in the global SCLC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for SCLC therapeutics in each of the markets covered.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
GlobalData

Our Clients